Vanda Receives EMA Orphan Drug Designation for Imsidolimab in GPP Treatment Market

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis: A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Vanda Pharmaceuticals Inc. announced that the Committee for Orphan Healthcare Products at the European Medicines Agency (EMA) has accepted a positive opinion recommending orphan drug designation for imsidolimab, the organization's investigational healthcare product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody for the management of generalized pustular psoriasis (GPP).

This marks the first time the EMA has granted orphan drug designation recognition for a drug to manage GPP in the European Union (EU). GPP is a severe, chronic, and possibly life-threatening inflammatory skin disorder, hereditarily and clinically distinct from plaque psoriasis, characterized by dysregulation in the interleukin-36 (IL-36) signalling pathway. It is characterized by extensive pustular eruptions, systemic inflammation, and serious complications, which lead to amplified mortality.

Imsidolimab inhibits IL-36 receptor signaling, speaking to the deficiency in the endogenous IL-36 receptor antagonist generally observed in patients with GPP.

The EMA's orphan medication designation is granted to therapeutic agents designed for the management of life-threatening or chronically debilitating rare conditions affecting fewer than 5 in 10,000 people in the EU. Advantages involve protocol assistance, lessening regulatory fees, and market exclusivity supplies in the EU following endorsement.

"The EMA's positive opinion is a significant milestone that reinforces the highly encouraging clinical data supporting the imsidolimab program and formally recognizes GPP as an orphan disease in the EU for the first time," said Dr. Mihael H. Polymeropoulos. "This designation highlights the urgent unmet medical need in GPP and brings us one step closer to delivering a meaningful new therapy to patients in the EU."

This designation tracks similar government recognitions in the United States and Japan. Furthermore, the imsidolimab Biologics License Application (BLA) for GPP is presently under review by the FDA, with a target reaction.

According to Towards Healthcare, the orphan drug market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 243.18 billion in 2026 to approximately USD 687.47 billion by 2035, representing a compound annual growth rate (CAGR) of 12.24% from 2026 to 2035. Orphan drugs are those developed particularly for the management of rare diseases. In the pharmaceutical sector, the drug advancement technology is long and classy, and achievement in terms of a marketable product is not guaranteed. Orphan drugs are applied for the management of a wider category of diseases known as orphan diseases. This involves not only rare diseases, but also those illnesses deserted or ignored by healthcare organizations, often because of their relatively reduced prevalence in the developed world. An orphan drug is a biopharmaceutical entity that is developed to treat some rare health conditions. An orphan drug would not be advantageous to produce without regulatory assistance, because of the small population of patients affected by the conditions. Orphan drugs usually follow the same government development path as any other pharmaceutical product, in which testing majorly focuses on pharmacokinetics and pharmacodynamics, stability, dosing, safety, and effectiveness.

About Vanda Pharmaceuticals

Vanda is a leading worldwide biopharmaceutical organization significantly focused on the advancement and commercialization of novel therapies to tackle the high unmet healthcare requirements and enhance the lives of consumers. Vanda is developing significant novel medicines to enhance the lives of patients. This company uses advanced technologies, involving genetics and genomics, to inform drug discovery, the company's clinical trials, and commercial positioning of compounds. Vanda Pharmaceuticals is working to advance the use of new strategies to deliver these novel therapeutics to patients. Vanda Pharmaceuticals Inc (Vanda) is a biopharmaceutical organization that develops and commercializes new therapies for the management of central nervous system disorders.  The organization targets markets in the US, Canada, and Europe. Vanda is headquartered in Washington, D.C., the US.

A recent report by Towards Healthcare highlights that the orphan drug market is witnessing growth because an orphan drug is a therapeutic agent developed particularly to manage a rare healthcare condition. Due to the small patient population, these drugs are generally not profitable under usual market conditions. Major uses of orphan drugs primarily focus on diagnosing, avoiding, or managing life-threatening and long-term debilitating rare diseases. Therapies like enzyme or protein replacement, gene-editing, and mRNA treatments for conditions such as Cystic Fibrosis, Spinal Muscular Atrophy, and Fabry disease. Orphan drugs are medicines with a special description because they manage rare or orphan diseases. The designation enables drug makers to develop these medicines and get them accepted.